Data Presented at IMAST shows over 99 percent accuracy when placing screws with Mazor Robotics Renaissance® Guidance System

ORLANDO, Fla., July 17, 2014 – <u>Mazor Robotics</u>, Ltd. (TASE: MZOR; NASDAQ GM: MZOR), a developer of innovative guidance systems and complementary products, announced results of data being presented July 16-19 at the $21^{\rm st}$ International Meeting on Advanced Spine Techniques (IMAST) meeting in Valencia, Spain.

An e-poster entitled, Retrospective, Five-Center Analysis of 3,270 Pedicle Screws Placed with Robotic Guidance in Adolescent Idiopathic Scoliosis (AIS), reports that 223 patients with AIS in five centers, had a total of 3,270 pedicle screws placed using the Renaissance system with over 99 percent accuracy.

A podium presentation, entitled: Retrospective Analysis of Feasibility and Performance of Robotic Guidance for Placement of Pedicle Screws in 223 Adolescents with Idiopathic Scoliosis (AIS), highlights that 3,270 screws were placed with the Renaissance system while fluoroscopy use was limited to 1.58 seconds per screw.

"Anatomic constraints in AIS frequently confound placement of pedicle screws, especially when instrumenting the most deformed regions of a curved spine," said Dr. Dennis P. Devito of Children's Healthcare of Atlanta, one of the lead investigators of the study. "The accuracy of screw placement and reduced exposure to radiation per case results in safer operations for both the patient and surgical staff."

Other researchers involved in the study included:

- Dr. Isador Lieberman, Texas Back Institute, Plano, TX
- Dr. Samuel Bederman, UCI Irvine Medical Center, Irvine, CA
- Dr. Raymond Woo, Florida Hospital for Children, Orlando, FL
- Dr. Sajan Hegde, Apollo Hospitals Chennai, Chennai, India

About The Renaissance System

Mazor Robotics Renaissance system is the only mechanical guidance system cleared by the US Food and Drug Administration for use in both spine and brain surgery.

To date, thousands of spine procedures have been performed with the Renaissance system, ranging from minimally-invasive one-level fusions to complex deformity reconstructions.

About Mazor

Mazor Robotics (TASE: MZOR; NASDAQGM: MZOR) believes in healing through innovation by developing and introducing revolutionary robotic-based technology and products aimed at redefining the gold standard of quality care. Mazor Robotics Renaissance[®] Guidance System enables surgeons to conduct spine and brain procedures in a more accurate and secure manner. For more information, please visit www.MazorRobotics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding the expectations for growth in system sales and recurring revenue, the Company's expected sales in 2016, and other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions are forward-looking statements. These statements are only predictions based on Mazor's current expectations and projections about future events.

There are important factors that could cause Mazor's actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor's filings with the Securities and Exchange Commission (SEC) including those discussed under the heading "Risk Factors" in Mazor's annual report on Form 20-F filed with the SEC on April 29, 2015 and in subsequent filings with the SEC. For more details, refer to Mazor's SEC filings. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.

U.S. Contacts: EVC Group

Michael Polyviou/Doug Sherk - Investors

mpolyviou@evcgroup.com; dsherk@evcgroup.com

212.850.6020; 646-445-4800

David Schemelia - Media

dave@evcgroup.com

646.201.5431

https://investors.mazorrobotics.com/press-releases?item=40